89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common StockGlobeNewsWire • 03/24/23
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 03/22/23
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver DiseaseInvestors Business Daily • 03/22/23
89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 WeeksGlobeNewsWire • 03/22/23
Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?Zacks Investment Research • 03/15/23
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/10/23
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of CardiologyGlobeNewsWire • 03/04/23
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of CardiologyGlobeNewsWire • 02/21/23
89BIO (ETNB) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/17/23